A Phase i study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 165-172

  Infante, J R ^a   Kurzrock, R ^b   Spratlin, J ^c   Burris, H A ^a   Eckhardt, S G ^c   Li, J ^d   Wu, K ^d   Skolnik, J M ^d   Hylander Gans, L ^d   Osmukhina, A ^d   Huszar, D ^d   Herbst, R S ^e  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

^e YALE CANCER CENTER   (United States)

Author keywords

AZD4877; Eg5; Pharmacokinetics; Safety; Solid tumors; Tolerability

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; KINESIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLADDER CANCER; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; INTESTINE OBSTRUCTION; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; SOFT TISSUE CANCER; SOLID TUMOR; STEADY STATE; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KINESIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PYRIMIDINONES; SEVERITY OF ILLNESS INDEX;

EID: 84856745726     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1667-z     Document Type: Article

References (25)

1. S Inoue ED Salmon 1995 Force generation by microtubule assembly/disassembly in mitosis and related movements Mol Biol Cell 6 1619 1640 8590794 1:CAS:528:DyaK2MXpvVWntLs%3D
2. DA Compton 2000 Spindle assembly in animal cells Annu Rev Biochem 69 95 114 10966454 10.1146/annurev.biochem.69.1.95 1:CAS:528:DC%2BD3cXnt1ajtLo%3D
3. A Blangy HA Lane P d'Herin M Harper M Kress EA Nigg 1995 Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo Cell 83 1159 1169 8548803 10.1016/0092-8674(95)90142-6 1:CAS:528:DyaK28XhsVOntw%3D%3D
4. R Sakowicz JT Finer C Beraud A Crompton E Lewis A Fritsch Y Lee J Mak R Moody R Turincio JC Chabala P Gonzales S Roth S Weitman KW Wood 2004 Antitumor activity of a kinesin inhibitor Cancer Res 64 3276 3280 15126370 10.1158/0008-5472.CAN-03-3839 1:CAS:528:DC%2BD2cXjs1ehtLY%3D (Pubitemid 38581433)
5. PS Hedge J Cogswell J Carrick J Jackson KW Wood WK Eng M Brawner PS Huang D Bergsma 2003 Differential gene expression analysis of kinesin spindle protein in human solid tumours Proc Am Soc Clin Oncol 22 abst 535
6. A Castillo HC Morse III VL Godfrey R Naeem MJ Justice 2007 Overexpression of Eg5 causes genomic instability and tumor formation in mice Cancer Res 67 10138 10147 17974955 10.1158/0008-5472.CAN-07-0326 1:CAS:528:DC%2BD2sXht1erur7P (Pubitemid 350070785)
7. A Masuda K Maeno T Nakagawa H Saito T Takahashi 2003 Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers Am J Pathol 163 1109 1116 12937152 10.1016/S0002-9440(10)63470-0 1:CAS:528:DC%2BD3sXnsVCisrY%3D (Pubitemid 37040146)
8. SS Taylor F McKeon 1997 Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage Cell 89 727 735 9182760 10.1016/S0092-8674(00)80255-X 1:CAS:528: DyaK2sXjs1ejsL8%3D (Pubitemid 27516175)
9. N Hayashi E Koller L Fazli ME Gleave 2008 Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity Prostate 68 1283 1295 18512732 10.1002/pros.20783 1:CAS:528:DC%2BD1cXhtFaqsbnO
10. TM Kapoor TU Mayer ML Coughlin TJ Mitchison 2000 Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5 J Cell Biol 150 975 988 10973989 10.1083/jcb.150.5.975 1:CAS:528: DC%2BD3cXmtlegt70%3D
11. M Liu H Yu L Huo J Liu M Li J Zhou 2008 Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor Biochem Pharmacol 76 169 178 18539263 10.1016/j.bcp.2008.04.018 1:CAS:528:DC%2BD1cXnvVGmtLs%3D
12. R Nakai S Iida T Takahashi T Tsujita S Okamoto C Takada K Akasaka S Ichikawa H Ishida H Kusaka S Akinaga C Murakata S Honda M Nitta H Saya Y Yamashita 2009 K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells Cancer Res 69 3901 3909 19351824 10.1158/0008-5472.CAN-08-4373 1:CAS:528:DC%2BD1MXltFOksLY%3D
13. Y Zhang W Xu 2008 Progress on kinesin spindle protein inhibitors as anti-cancer agents Anticancer Agents Med Chem 8 698 704 18690830 1:CAS:528:DC%2BD1cXps1Ogsrs%3D
14. TU Mayer TM Kapoor SJ Haggarty RW King SL Schreiber TJ Mitchison 1999 Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 286 971 974 10542155 10.1126/science.286.5441.971 1:CAS:528:DyaK1MXntFaqu7o%3D
15. GA Orr P Verdier-Pinard H McDaid SB Horwitz 2003 Mechanisms of Taxol resistance related to microtubules Oncogene 22 7280 7295 14576838 10.1038/sj.onc.1206934 1:CAS:528:DC%2BD3sXotlajtbc%3D (Pubitemid 37487160)
16. Pinzon-Ortiz MC, Cao A, Sheehy A, Pablo L, McEachern K, Hylander-Gans L, Wu K, Reimer C, Morosini D, McCoon P, Huszar D (2010) Characterization of the kinesin spindle protein inhibitor AZD4877. In: AACR annual meeting, p abst 4429
17. Declaration of Helsinki. Ethical principles for medical research involving human subjects (1964) World Medical Association
18. American Society of Clinical Oncology 1994 Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines J Clin Oncol 12 2471 2508
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
20. D Huszar ME Theoclitou J Skolnik R Herbst 2009 Kinesin motor proteins as targets for cancer therapy Cancer Metastasis Rev 28 197 208 19156502 10.1007/s10555-009-9185-8 1:CAS:528:DC%2BD1MXjsVWntrg%3D
21. JJ Knox S Gill T Synold JJ Biagi P Major R Feld C Cripps N Wainman E Eisenhauer L Seymour 2008 A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168) Invest New Drugs 26 265 272 18196204 10.1007/s10637-007-9103-2 1:CAS:528: DC%2BD1cXkvFyjsLk%3D
22. CW Lee K Belanger SC Rao TM Petrella RG Tozer L Wood KJ Savage EA Eisenhauer TW Synold N Wainman 2008 A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial Invest New Drugs 26 249 255 17962907 10.1007/s10637-007-9097-9 1:CAS:528:DC%2BD1cXkvFyjsrg%3D (Pubitemid 351579684)
23. PA Tang LL Siu EX Chen SJ Hotte S Chia JK Schwarz GR Pond C Johnson AD Colevas TW Synold LS Vasist 2008 Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck Invest New Drugs 26 257 264 18038218 10.1007/s10637-007-9098-8 1:CAS:528:DC%2BD1cXkvFyjsbo%3D
24. RT Lee KE Beekman M Hussain NB Davis JI Clark SP Thomas KF Nichols WM Stadler 2008 A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer Clin Genitourin Cancer 6 21 24 18501078 10.3816/CGC.2008.n.003 1:CAS:528:DC%2BD1cXmtFOms7g%3D (Pubitemid 351656239)
25. TM Beer B Goldman TW Synold CW Ryan LS Vasist VP Van Jr SR Dakhil PN Lara Jr A Drelichman MH Hussain ED Crawford 2008 Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes Clin Genitourin Cancer 6 103 109 18824433 10.3816/CGC.2008.n.016 1:CAS:528:DC%2BD1cXhtlWnurzK